Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland
Oddur Ingimarsson Artikkel Engelsk
*0011268077 *008171212s2017 xx# 000 0 eng *019 $bk *08230$a616.898061 *100 $aOddur Ingimarsson$4aut$_146220800 *245 $aRisk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland *300 $aS. 496-502 : ill. *500 $aVitenskapelig artikkel *650 $aantipsykotika$9nor$2norart$_129712100 *650 $adyslipidemier$9nor$2norart$_144690600 *650 $aschizofreni$9nor$2norart$_128828500 *650 $atype 2 diabetes$9nor$2norart$_128979300 *651 $aIsland$_10467100 *653 $aClozapine$9eng$_142679100 *653 $adiabetes$9eng$_131901500 *653 $adyslipidemia$9eng$_147040600 *653 $ametabolic$9eng$_148821200 *653 $aschizophrenia$9eng$_128835300 *700 $aEngilbert Sigurdsson$4aut$_134860200 *700 $aHalldóra Jónsdóttir;$4aut$_146221200 *700 $aMacCabe, James H.;$4aut$_146221300 *700 $aMagnús Haraldsson;$4aut$_146221400 *773 $tNordic journal of psychiatry [elektronisk ressurs]$gVol. 71, no. 7 (2017)$x1502-4725 *8564 $uhttps://doi.org/10.1080/08039488.2017.1334821 *999 $z1700621840$anorart:1700621840 ^